From NPC therapeutic target identification to potential treatment strategy

Ming Ying Lan, Chi Long Chen, Kuan Ting Lin, Sheng An Lee, Wu Lung R Yang, Chun Nan Hsu, Jaw Ching Wu, Ching Yin Ho, Jin Ching Lin, Chi Ying F Huang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Nasopharyngeal carcinoma (NPC) is relatively rare in Western countries but is a common cancer in southern Asia. Many differentially expressed genes have been linked to NPC; however, how to prioritize therapeutic targets and potential drugs from unsorted gene lists remains largely unknown. We first collected 558 upregulated and 993 downregulated NPC genes from published microarray data and the primary literatures. We then postulated that conversion of gene signatures into the protein-protein interaction network and analyzing the network topologically could provide insight into key regulators involved in tumorigenesis of NPC. Of particular interest was the presence of cliques, called fully connected subgraphs, in the inferred NPC networks. These clique-based hubs, connecting with more than three queries and ranked higher than other nodes in the NPC protein-protein interaction network, were further narrowed down by pathway analysis to retrieve 24 upregulated and 6 downregulated bottleneck genes for predicting NPC carcinogenesis. Moreover, additional oncogenes, tumor suppressor genes, genes involved in protein complexes, and genes obtained after functional profiling were merged with the bottleneck genes to form the final gene signature of 38 upregulated and 10 downregulated genes. We used the initial and final NPC gene signatures to query the Connectivity Map, respectively, and found that target reduction through our pipeline could efficiently uncover potential drugs with cytotoxicity to NPC cancer cells. An integrative Web site (http://140.109.23.188:8080/NPC) was established to facilitate future NPC research. This in silico approach, from target prioritization to potential drugs identification, might be an effective method for various cancer researches.

Original languageEnglish
Pages (from-to)2511-2523
Number of pages13
JournalMolecular Cancer Therapeutics
Volume9
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Genes
Protein Interaction Maps
Therapeutics
Down-Regulation
Carcinogenesis
Nasopharyngeal carcinoma
Pharmaceutical Preparations
Nasopharyngeal Neoplasms
Gene Conversion
Proteins
Tumor Suppressor Genes
Oncogenes
Research
Computer Simulation
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lan, M. Y., Chen, C. L., Lin, K. T., Lee, S. A., Yang, W. L. R., Hsu, C. N., ... Huang, C. Y. F. (2010). From NPC therapeutic target identification to potential treatment strategy. Molecular Cancer Therapeutics, 9(9), 2511-2523. https://doi.org/10.1158/1535-7163.MCT-09-0966

From NPC therapeutic target identification to potential treatment strategy. / Lan, Ming Ying; Chen, Chi Long; Lin, Kuan Ting; Lee, Sheng An; Yang, Wu Lung R; Hsu, Chun Nan; Wu, Jaw Ching; Ho, Ching Yin; Lin, Jin Ching; Huang, Chi Ying F.

In: Molecular Cancer Therapeutics, Vol. 9, No. 9, 09.2010, p. 2511-2523.

Research output: Contribution to journalArticle

Lan, MY, Chen, CL, Lin, KT, Lee, SA, Yang, WLR, Hsu, CN, Wu, JC, Ho, CY, Lin, JC & Huang, CYF 2010, 'From NPC therapeutic target identification to potential treatment strategy', Molecular Cancer Therapeutics, vol. 9, no. 9, pp. 2511-2523. https://doi.org/10.1158/1535-7163.MCT-09-0966
Lan, Ming Ying ; Chen, Chi Long ; Lin, Kuan Ting ; Lee, Sheng An ; Yang, Wu Lung R ; Hsu, Chun Nan ; Wu, Jaw Ching ; Ho, Ching Yin ; Lin, Jin Ching ; Huang, Chi Ying F. / From NPC therapeutic target identification to potential treatment strategy. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 9. pp. 2511-2523.
@article{78abcaab798f4233b422767ce86ed5ec,
title = "From NPC therapeutic target identification to potential treatment strategy",
abstract = "Nasopharyngeal carcinoma (NPC) is relatively rare in Western countries but is a common cancer in southern Asia. Many differentially expressed genes have been linked to NPC; however, how to prioritize therapeutic targets and potential drugs from unsorted gene lists remains largely unknown. We first collected 558 upregulated and 993 downregulated NPC genes from published microarray data and the primary literatures. We then postulated that conversion of gene signatures into the protein-protein interaction network and analyzing the network topologically could provide insight into key regulators involved in tumorigenesis of NPC. Of particular interest was the presence of cliques, called fully connected subgraphs, in the inferred NPC networks. These clique-based hubs, connecting with more than three queries and ranked higher than other nodes in the NPC protein-protein interaction network, were further narrowed down by pathway analysis to retrieve 24 upregulated and 6 downregulated bottleneck genes for predicting NPC carcinogenesis. Moreover, additional oncogenes, tumor suppressor genes, genes involved in protein complexes, and genes obtained after functional profiling were merged with the bottleneck genes to form the final gene signature of 38 upregulated and 10 downregulated genes. We used the initial and final NPC gene signatures to query the Connectivity Map, respectively, and found that target reduction through our pipeline could efficiently uncover potential drugs with cytotoxicity to NPC cancer cells. An integrative Web site (http://140.109.23.188:8080/NPC) was established to facilitate future NPC research. This in silico approach, from target prioritization to potential drugs identification, might be an effective method for various cancer researches.",
author = "Lan, {Ming Ying} and Chen, {Chi Long} and Lin, {Kuan Ting} and Lee, {Sheng An} and Yang, {Wu Lung R} and Hsu, {Chun Nan} and Wu, {Jaw Ching} and Ho, {Ching Yin} and Lin, {Jin Ching} and Huang, {Chi Ying F}",
year = "2010",
month = "9",
doi = "10.1158/1535-7163.MCT-09-0966",
language = "English",
volume = "9",
pages = "2511--2523",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - From NPC therapeutic target identification to potential treatment strategy

AU - Lan, Ming Ying

AU - Chen, Chi Long

AU - Lin, Kuan Ting

AU - Lee, Sheng An

AU - Yang, Wu Lung R

AU - Hsu, Chun Nan

AU - Wu, Jaw Ching

AU - Ho, Ching Yin

AU - Lin, Jin Ching

AU - Huang, Chi Ying F

PY - 2010/9

Y1 - 2010/9

N2 - Nasopharyngeal carcinoma (NPC) is relatively rare in Western countries but is a common cancer in southern Asia. Many differentially expressed genes have been linked to NPC; however, how to prioritize therapeutic targets and potential drugs from unsorted gene lists remains largely unknown. We first collected 558 upregulated and 993 downregulated NPC genes from published microarray data and the primary literatures. We then postulated that conversion of gene signatures into the protein-protein interaction network and analyzing the network topologically could provide insight into key regulators involved in tumorigenesis of NPC. Of particular interest was the presence of cliques, called fully connected subgraphs, in the inferred NPC networks. These clique-based hubs, connecting with more than three queries and ranked higher than other nodes in the NPC protein-protein interaction network, were further narrowed down by pathway analysis to retrieve 24 upregulated and 6 downregulated bottleneck genes for predicting NPC carcinogenesis. Moreover, additional oncogenes, tumor suppressor genes, genes involved in protein complexes, and genes obtained after functional profiling were merged with the bottleneck genes to form the final gene signature of 38 upregulated and 10 downregulated genes. We used the initial and final NPC gene signatures to query the Connectivity Map, respectively, and found that target reduction through our pipeline could efficiently uncover potential drugs with cytotoxicity to NPC cancer cells. An integrative Web site (http://140.109.23.188:8080/NPC) was established to facilitate future NPC research. This in silico approach, from target prioritization to potential drugs identification, might be an effective method for various cancer researches.

AB - Nasopharyngeal carcinoma (NPC) is relatively rare in Western countries but is a common cancer in southern Asia. Many differentially expressed genes have been linked to NPC; however, how to prioritize therapeutic targets and potential drugs from unsorted gene lists remains largely unknown. We first collected 558 upregulated and 993 downregulated NPC genes from published microarray data and the primary literatures. We then postulated that conversion of gene signatures into the protein-protein interaction network and analyzing the network topologically could provide insight into key regulators involved in tumorigenesis of NPC. Of particular interest was the presence of cliques, called fully connected subgraphs, in the inferred NPC networks. These clique-based hubs, connecting with more than three queries and ranked higher than other nodes in the NPC protein-protein interaction network, were further narrowed down by pathway analysis to retrieve 24 upregulated and 6 downregulated bottleneck genes for predicting NPC carcinogenesis. Moreover, additional oncogenes, tumor suppressor genes, genes involved in protein complexes, and genes obtained after functional profiling were merged with the bottleneck genes to form the final gene signature of 38 upregulated and 10 downregulated genes. We used the initial and final NPC gene signatures to query the Connectivity Map, respectively, and found that target reduction through our pipeline could efficiently uncover potential drugs with cytotoxicity to NPC cancer cells. An integrative Web site (http://140.109.23.188:8080/NPC) was established to facilitate future NPC research. This in silico approach, from target prioritization to potential drugs identification, might be an effective method for various cancer researches.

UR - http://www.scopus.com/inward/record.url?scp=77956596734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956596734&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0966

DO - 10.1158/1535-7163.MCT-09-0966

M3 - Article

C2 - 20716640

AN - SCOPUS:77956596734

VL - 9

SP - 2511

EP - 2523

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -